Literature DB >> 1623301

Reduced peptide bond pseudopeptide analogues of neurotensin.

S Doulut1, M Rodriguez, D Lugrin, F Vecchini, P Kitabgi, A Aumelas, J Martinez.   

Abstract

Pseudopeptide analogues of the C-terminal hexapeptide of neurotensin (H-Arg-Arg-Pro-Tyr-Ile-Leu-OH) were obtained by replacing each peptide bond by the reduced peptide bond CH2NH. The resulting analogues were then examined for their ability to inhibit binding of labeled neurotensin to new-born mouse brain membranes and for stimulation of guinea pig ileum contraction. Replacement of the Ile12-Leu13, Tyr11-Ile12, Pro10-Tyr11 and Lys9-Pro10 peptide bonds resulted in about 2000-, 3400-, 200- and 3400-fold losses, respectively, in binding affinity and 400-, 750-, 250- and 300-fold losses, respectively, in biological activity. Replacement of both Arg8 and Arg9 by lysine led to an analogue exhibiting the same pharmacological profile as the C-terminal hexapeptide of neurotensin. Interestingly, replacement of the Lys8-Lys9 peptide bond by the CH2NH bond produced an analogue exhibiting the same affinity for neurotensin receptors, but 10 times more potent in stimulating guinea pig ileum contraction. N-terminal protected analogues (by the Boc group) showed decreased potency as compared with their amino-free corresponding compounds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623301

Source DB:  PubMed          Journal:  Pept Res        ISSN: 1040-5704


  7 in total

1.  Identification of the receptor subtype involved in the analgesic effect of neurotensin.

Authors:  I Dubuc; P Sarret; C Labbé-Jullié; J M Botto; E Honoré; E Bourdel; J Martinez; J Costentin; J P Vincent; P Kitabgi; J Mazella
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

2.  Heightened Exploratory Behavior Following Chronic Excessive Ethanol Drinking: Mediation by Neurotensin Receptor Type 2 in the Anterior Paraventricular Thalamus.

Authors:  Surya Pandey; Jessica R Barson
Journal:  Alcohol Clin Exp Res       Date:  2020-07-26       Impact factor: 3.455

3.  Regulation of the neurotensin NT(1) receptor in the developing rat brain following chronic treatment with the antagonist SR 48692.

Authors:  I Lépée-Lorgeoux; C Betancur; F Souazé; W Rostène; A Bérod; D Pélaprat
Journal:  J Neurosci Res       Date:  2000-05-01       Impact factor: 4.164

4.  The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2015-04-03       Impact factor: 2.823

5.  Transcriptional regulation of the tyrosine hydroxylase gene by neurotensin in human neuroblastoma CHP212 cells.

Authors:  M Najimi; E Hermans; W Rostène; P Forgez
Journal:  Metab Brain Dis       Date:  2001-12       Impact factor: 3.584

6.  [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

Authors:  Theodosia Maina; Anastasia Nikolopoulou; Eleni Stathopoulou; Athanassios S Galanis; Paul Cordopatis; Berthold A Nock
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-27       Impact factor: 9.236

7.  Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.